Results 121 to 130 of about 13,322 (172)

Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025. [PDF]

MMWR Morb Mortal Wkly Rep
Amin AB, Collins JP, Dong X, Leidner AJ, Loehr J, Moser CA, McNamara LA.   +6 more
europepmc   +1 more source

Temporal trends of vaccination coverage in children under five in Brazil, 1998-2024. [PDF]

BMC Public Health
Rago CAP, de Novais MAP, Zucchi P.
europepmc   +1 more source

Prevention of neuroinfectious-diseases: high impact of vaccination programs - but the potential is not maxed out yet. [PDF]

Neurol Res Pract
Klein M, Schöls M, Tumani H, Meyding-Lamade U, Decker J, Maschke M, Wagner J.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Meningococcal Vaccines

Infectious Disease Clinics of North America, 2001
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein, M, Fischer, J W, Tappero   +2 more
openaire   +2 more sources

Meningococcal carriage, meningococcal disease and vaccination

Journal of Infection, 1988
Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%)
M K, Hassan-King, R A, Wall, B M, Greenwood   +2 more
openaire   +2 more sources

Meningococcal conjugate vaccines

Expert Opinion on Pharmacotherapy, 2004
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
Shanta M, Zimmer, David S, Stephens
openaire   +2 more sources

The Future of Meningococcal Vaccines

Pediatric Infectious Disease Journal, 2005
Despite antibiotics and supportive care ~10% of persons with meningococcal infection die 9-19% have sequelae (skin grafting amputation hearing deficits) and outbreaks often provoke panic. Meningococcal meningitis is the main cause of bacterial meningitis in children in the United States.
C Mary, Healy, Carol J, Baker
openaire   +2 more sources

Bioanalysis of Meningococcal Vaccines

Bioanalysis, 2010
Meningococcal meningitis is feared because of the rapid onset of severe disease from mild symptoms and, therefore, is an important target for vaccine research. Five serogroups, defined by the structures of their capsular polysaccharides, are responsible for the vast majority of disease.
Neil, Ravenscroft, Jun X, Wheeler, Christopher, Jones   +2 more
openaire   +2 more sources